Literature DB >> 20888396

Motor neuron-specific overexpression of the presynaptic choline transporter: impact on motor endurance and evoked muscle activity.

D Lund1, A M Ruggiero, S M Ferguson, J Wright, B A English, P A Reisz, S M Whitaker, A C Peltier, R D Blakely.   

Abstract

The presynaptic, hemicholinium-3 sensitive, high-affinity choline transporter (CHT) supplies choline for acetylcholine (ACh) synthesis. In mice, a homozygous deletion of CHT (CHT-/-) leads to premature cessation of spontaneous or evoked neuromuscular signaling and is associated with perinatal cyanosis and lethality within 1 h. Heterozygous (CHT+/-) mice exhibit diminished brain ACh levels and demonstrate an inability to sustain vigorous motor activity. We sought to explore the contribution of CHT gene dosage to motor function in greater detail using transgenic mice where CHT is expressed under control of the motor neuron promoter Hb9 (Hb9:CHT). On a CHT-/- background, the Hb9:CHT transgene conferred mice with the ability to move and breath for a postnatal period of ∼24 h, thus increasing survival. Conversely, Hb9:CHT expression on a wild-type background (CHT+/+;Hb9:CHT) leads to an increased capacity for treadmill running compared to wild-type littermates. Analysis of the stimulated compound muscle action potential (CMAP) in these animals under basal conditions established that CHT+/+;Hb9:CHT mice display an unexpected, bidirectional change, producing either elevated or reduced CMAP amplitude, relative to CHT+/+ animals. To examine whether these two groups arise from underlying changes in synaptic properties, we used high-frequency stimulation of motor axons to assess CMAP recovery kinetics. Although CHT+/+; Hb9:CHT mice in the two groups display an equivalent, time-dependent reduction in CMAP amplitude, animals with a higher basal CMAP amplitude demonstrate a significantly enhanced rate of recovery. To explain our findings, we propose a model whereby CHT support for neuromuscular signaling involves contributions to ACh synthesis as well as cholinergic synaptic vesicle availability.
Copyright © 2010 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20888396      PMCID: PMC2992794          DOI: 10.1016/j.neuroscience.2010.09.057

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  49 in total

Review 1.  Safety factor at the neuromuscular junction.

Authors:  S J Wood; C R Slater
Journal:  Prog Neurobiol       Date:  2001-07       Impact factor: 11.685

2.  Sex differences in neurochemical markers that correlate with behavior in aging mice.

Authors:  K M Frick; L A Burlingame; S S Delaney; J Berger-Sweeney
Journal:  Neurobiol Aging       Date:  2002 Jan-Feb       Impact factor: 4.673

3.  Post-exercise facilitation and depression of M wave and motor evoked potentials in healthy subjects.

Authors:  Marianne Lentz; Jørgen Feldbaek Nielsen
Journal:  Clin Neurophysiol       Date:  2002-07       Impact factor: 3.708

4.  Roles of neurotransmitter in synapse formation: development of neuromuscular junctions lacking choline acetyltransferase.

Authors:  Thomas Misgeld; Robert W Burgess; Renate M Lewis; Jeanette M Cunningham; Jeff W Lichtman; Joshua R Sanes
Journal:  Neuron       Date:  2002-11-14       Impact factor: 17.173

5.  Interstrain variation in murine aerobic capacity.

Authors:  J T Lightfoot; M J Turner; K A Debate; S R Kleeberger
Journal:  Med Sci Sports Exerc       Date:  2001-12       Impact factor: 5.411

6.  Genetic variability in forced and voluntary endurance exercise performance in seven inbred mouse strains.

Authors:  Imanuel Lerman; Brooke C Harrison; Kalev Freeman; Timothy E Hewett; David L Allen; Jeffrey Robbins; Leslie A Leinwand
Journal:  J Appl Physiol (1985)       Date:  2002-06

7.  Tachycardia, reduced vagal capacity, and age-dependent ventricular dysfunction arising from diminished expression of the presynaptic choline transporter.

Authors:  Brett A English; Martin Appalsamy; Andre Diedrich; Alicia M Ruggiero; David Lund; Jane Wright; Nancy R Keller; Katherine M Louderback; David Robertson; Randy D Blakely
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-07-02       Impact factor: 4.733

8.  Aberrant patterning of neuromuscular synapses in choline acetyltransferase-deficient mice.

Authors:  Eugene P Brandon; Weichun Lin; Kevin A D'Amour; Donald P Pizzo; Bertha Dominguez; Yoshie Sugiura; Silke Thode; Chien-Ping Ko; Leon J Thal; Fred H Gage; Kuo-Fen Lee
Journal:  J Neurosci       Date:  2003-01-15       Impact factor: 6.167

9.  Vesicular localization and activity-dependent trafficking of presynaptic choline transporters.

Authors:  Shawn M Ferguson; Valentina Savchenko; Subbu Apparsundaram; Melissa Zwick; Jane Wright; Craig J Heilman; Hong Yi; Allan I Levey; Randy D Blakely
Journal:  J Neurosci       Date:  2003-10-29       Impact factor: 6.167

10.  Altered striatal function and muscarinic cholinergic receptors in acetylcholinesterase knockout mice.

Authors:  Laura A Volpicelli-Daley; Anna Hrabovska; Ellen G Duysen; Shawn M Ferguson; Randy D Blakely; Oksana Lockridge; Allan I Levey
Journal:  Mol Pharmacol       Date:  2003-12       Impact factor: 4.436

View more
  7 in total

1.  Acetylcholine receptors in the equatorial region of intrafusal muscle fibres modulate mouse muscle spindle sensitivity.

Authors:  Laura Gerwin; Corinna Haupt; Katherine A Wilkinson; Stephan Kröger
Journal:  J Physiol       Date:  2019-02-13       Impact factor: 5.182

2.  Differential impact of genetically modulated choline transporter expression on the release of endogenous versus newly synthesized acetylcholine.

Authors:  Hideki Iwamoto; M Wade Calcutt; Randy D Blakely
Journal:  Neurochem Int       Date:  2016-03-22       Impact factor: 3.921

3.  Choline transporter hemizygosity results in diminished basal extracellular dopamine levels in nucleus accumbens and blunts dopamine elevations following cocaine or nicotine.

Authors:  Yu Dong; John A Dani; Randy D Blakely
Journal:  Biochem Pharmacol       Date:  2013-08-09       Impact factor: 5.858

4.  Time-of-flight secondary ion mass spectrometry based molecular histology of human spinal cord tissue and motor neurons.

Authors:  Jörg Hanrieder; Per Malmberg; Olle R Lindberg; John S Fletcher; Andrew G Ewing
Journal:  Anal Chem       Date:  2013-08-27       Impact factor: 6.986

5.  Transgenic overexpression of the presynaptic choline transporter elevates acetylcholine levels and augments motor endurance.

Authors:  Ericka C Holmstrand; David Lund; Ajeesh Koshy Cherian; Jane Wright; Rolicia F Martin; Elizabeth A Ennis; Gregg D Stanwood; Martin Sarter; Randy D Blakely
Journal:  Neurochem Int       Date:  2013-11-22       Impact factor: 3.921

6.  B6eGFPChAT mice overexpressing the vesicular acetylcholine transporter exhibit spontaneous hypoactivity and enhanced exploration in novel environments.

Authors:  Paul M Nagy; Isabelle Aubert
Journal:  Brain Behav       Date:  2013-04-18       Impact factor: 2.708

7.  Identification and characterization of ML352: a novel, noncompetitive inhibitor of the presynaptic choline transporter.

Authors:  Elizabeth A Ennis; Jane Wright; Cassandra L Retzlaff; Owen B McManus; Zhinong Lin; Xiaofang Huang; Meng Wu; Min Li; J Scott Daniels; Craig W Lindsley; Corey R Hopkins; Randy D Blakely
Journal:  ACS Chem Neurosci       Date:  2015-02-02       Impact factor: 4.418

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.